News from BiOptix A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 26, 2014, 15:22 ET
Quantitative SPR Screening of Aptamer-Protein Interactions For Pre-Clinical Development using the BiOptix 404pi (PRNewsFoto/BiOptix)

BiOptix and Altermune Technologies Present at Drug Analysis 2014

 BiOptix, in conjunction with Altermune Technologies announced today the presentation of a poster for "Quantitative SPR Screening...

Jun 05, 2014, 11:11 ET

BiOptix Announces support for the 9th Annual Next Generation Protein Therapeutics Summit

 BiOptix is pleased to announce its participation in the 9th annual Next Generation Protein Therapeutics Summit, being held in conjunction with...

Feb 18, 2014, 14:18 ET

BiOptix Continues California Roadshow Highlighting New Publication Data

 With its participation in the 58th annual Biophysical Society Meeting from February 15 – 19, along with the 21st International Molecular...

Dec 11, 2013, 15:22 ET

BiOptix Continues Support of Antibody Engineering & Therapeutics Research

BiOptix continues support of the global antibody engineering and therapeutics research community through participation in IBC's 24th Annual...

Sep 26, 2013, 09:26 ET

BiOptix announces expansion of Innovators Program into Europe

 BiOptix formally announced the European expansion of the BiOptix Innovators Program at MipTec & BioValley Life Sciences Week, being held...

Jul 08, 2013, 13:13 ET

BiOptix announces low cost Surface Plasmon Resonance Services for Colorado-based researchers

BiOptix formally announces a unique to the industry research collaboration with the Biophysics Shared Resource Core Facility at the University of...

Jun 26, 2013, 17:39 ET

BiOptix announces support of the 8th Annual Next Generation Protein Therapeutics Summit

BiOptix today announced participation and support in IBC's 8th Annual Next Generation Protein Therapeutics Summit in San Diego, California. ...

Apr 08, 2013, 12:31 ET

BiOptix presents new and compelling kinetics data in the fight against cancer

BiOptix will present new and compelling PSA (Prostate-Specific Antigen) data from the BiOptix 404pi, the first commercially available SPR...

Feb 27, 2013, 14:27 ET

BiOptix to highlight new carbonic anhydrase data at IBC's Biopharmaceutical Development & Production Week

BiOptix is highlighting new and compelling small molecule kinetics data from the new BiOptix 404pi at the IBC Biopharmaceutical Development &...

Feb 12, 2013, 14:12 ET

BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013

 BiOptix in conjunction with Molecular Med TRI-CON 2013 will officially announce the expansion of the BiOptix Innovators Program, a...

Dec 03, 2012, 12:03 ET

BiOptix announces a new SPR technology for Antibody Manufacturers and Researchers

 BiOptix announced today that it will be showcasing the new BiOptix 404pi at IBC's 23rd Annual Antibody Engineering and Therapeutics Conference...

Nov 01, 2012, 11:01 ET

BiOptix to highlight new 404pi instrument at European symposia

BiOptix today announced that it would be highlighting the new BiOptix 404pi, the first commercially available SPR instrument to incorporate...

Oct 25, 2012, 10:25 ET

BiOptix announces the launch of the BiOptix Innovators Program

 BiOptix today announced the BiOptix Innovators Program, a pioneering instrument trial program that encourages researchers and institutions to...

Sep 24, 2012, 09:24 ET

BiOptix Announces Expansion of Sales and Marketing Efforts into Europe.

BiOptix officially announced that it has expanded sales and marketing efforts outside of the United States and into Europe with participation in...

Sep 11, 2012, 09:11 ET

BiOptix Participates in Leading Life Sciences Event BioWest 2012

BiOptix announced continued support of the Colorado BioScience Association today, with participation in BioWest 2012, a leading life sciences...

Aug 22, 2012, 08:22 ET
BiOptix Diagnostics Corporation, a privately held firm based in Boulder, Colorado has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR -- Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction -- with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  (PRNewsFoto/BiOptix)

BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule

BiOptix today officially announced its fall 2012 Tradeshow and Symposia schedule.  These events will highlight the BiOptix Enhanced Surface...

Jun 27, 2012, 16:45 ET

BiOptix announces expansion of Board of Directors

BiOptix announces the appointment of Michael W. Routh, Ph. D. to the Board of Directors of the firm, adding to a preeminent group of leaders...

Jun 15, 2012, 15:25 ET

BiOptix continues support of Colorado-based research institutions

 BiOptix, a Colorado-based firm, announces completion of a successful week of research shows in Colorado's Biotech Corridor. BiOptix today...

Apr 30, 2012, 08:00 ET

BiOptix Announces Support of the 8th Annual PEGS Summit

 BiOptix today announced participation in the 8th Annual PEGS:  Protein Engineering Summit, to be held in Boston April 30 – May 4,...

Apr 26, 2012, 14:00 ET

BiOptix Unveils a New Brand Identity reflecting an expansion into the Surface Plasmon Resonance (SPR) Marketplace with a novel and patented technology

 BiOptix today formally unveiled a new corporate brand identity and tag line: "Kinetics with Confidence," which is designed to promote...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets